Evidence map›Paper›PMID 37927364›Full record

ArticleSAGE open medical case reports2023

Levothyroxine liquid oral substitution as an alternative treatment for refractory hypothyroidism due to gastrointestinal malabsorption: A case report.

Faten Cherchir, Ibtissem Oueslati, Yasmine Mouelhi, Emna Talbi, Moncef Feki, Meriem Yazidi, Melika Chihaoui

Open access · goldAbstract readCase Reports
In one paragraph

Article in SAGE open medical case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Faten CherchirFaculty of Medicine of Tunis, Department of Endocrinology, La Rabta University Hospital, University of Tunis El Manar, Tunis, Tunisia.
Ibtissem OueslatiFaculty of Medicine of Tunis, Department of Endocrinology, La Rabta University Hospital, University of Tunis El Manar, Tunis, Tunisia.ORCID https://orcid.org/0000-0002-4278-9447
Yasmine MouelhiFaculty of Medicine of Tunis, Department of Endocrinology, La Rabta University Hospital, University of Tunis El Manar, Tunis, Tunisia.
Emna TalbiFaculty of Medicine of Tunis, Laboratory of Biochemistry, La Rabta University Hospital, University of Tunis El Manar, Tunis, Tunisia.
Moncef FekiFaculty of Medicine of Tunis, Laboratory of Biochemistry, La Rabta University Hospital, University of Tunis El Manar, Tunis, Tunisia.
Meriem YazidiFaculty of Medicine of Tunis, Department of Endocrinology, La Rabta University Hospital, University of Tunis El Manar, Tunis, Tunisia.
Melika ChihaouiFaculty of Medicine of Tunis, Department of Endocrinology, La Rabta University Hospital, University of Tunis El Manar, Tunis, Tunisia.
Faculté de médecine de TunisTunis El Manar University · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tablets of levothyroxine (LT4) are the most used form for the treatment of hypothyroidism. Some patients may present with refractory hypothyroidism despite a high daily LT4 dose. We report the case of a 49-year-old woman who was admitted to our department for refractory hypothyroidism. She was treated with 300 μg oral LT4 tablets daily (3.9 μg/kg/day). Despite good compliance and regular intake of high doses of LT4, she had persistent symptoms of hypothyroidism and a thyroid-stimulating hormone level of 92.4 mIU/L. LT4 absorption test was consistent with the diagnosis of malabsorption. Etiological investigations revealed Helicobacter pylori gastritis. Helicobacter infection was adequately treated, but symptoms of hypothyroidism and elevated thyroid-stimulating hormone persisted. Increased LT4 doses (400 μg) failed to normalize thyroid-stimulating hormone levels. Thus, she was put on LT4 liquid form at a dose of 80 drops/day per day (400 µg). Two weeks later, she presented with clinical and biological improvement with a normal free thyroxine level of 1.14 ng/dL. Patients with gastrointestinal disorders may present with refractory hypothyroidism despite increasing doses of LT4. Switching to liquid formulation may resolve this problem.

Indexed as

levothyroxinelevothyroxine absorption testmalabsorptionRefractory hypothyroidism

Identifiers

PMID37927364
PMCPMC10623934
OpenAlexW4388227471

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.